Back
Notification report
Full notification file
General information
Notification Number
B/ES/13/18
Member State to which the notification was sent
Spain
Date of acknowledgement from the Member State Competent Authority
12/03/2013
Title of the Project
Phase I Clinical Trial of Delta-24-RGD oncolytic adenovirus and
temozolomide for treatment of glioblastoma at first recurrence
Proposed period of release:
01/04/2013 to 01/04/2015
Name of the Institute(s) or Company(ies)
Clínica Universidad de Navarra, ;
3. Is the same GMO release planned elsewhere in the Community?
No
Has the same GMO been notified elsewhere by the same notifier?
No
GMO characterization
GMO is a:
DNA Virus
Identity of the GMO:
Genus: Mastadenovirus
Species: human adenovirus
The GMO (Delta24-RGD-4C) is an oncolytic adenovirus, which is a replication competent virus selective of tumoral cells. Its genome contains 2 genetic modifications with respect to the wild typevirus (Ad5).
Information relating to the recipient or parental organisms from wich the GMO is derived
Common Name
Genus
Species
Subspecies
Strain
Pathovar
Adenovirus human serotype 5 (Ad5)
Mastadenovirus
human adenovirus
subgroup C
human serotype 5 (Ad5)
-
European Commission administrative information
Consent given by the Member State Competent Authority:
Yes
17/05/2013 00:00:00
Remarks:
